Gossamer Bio and Chiesi partner for pulmonary hypertension treatment

Pharmaceutical Technology· Joyseulay / Shutterstock.com.
GlobalData
2 min read
0
In this article:

Gossamer Bio and Chiesi Farmaceutici (the Chiesi Group) have announced a worldwide partnership and licence agreement to develop and market seralutinib for pulmonary hypertension.

The partnership will leverage the strengths of both companies to enhance efforts in treating pulmonary arterial hypertension (PAH) and to expedite the product development for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Chiesi will offer its global expertise in respiratory and rare disease treatment, as well as inhaled drug development and commercialisation while Gossamer will contribute PAH and PH-ILD development and commercialisation teams.

Seralutinib is administered via a dry powder inhaler.

The collaboration follows the positive outcome of the Phase II TORREY clinical trial in PAH patients, prompting Gossamer to launch the Phase III PROSERA study in 2023.

The companies will begin an international Phase III registration study of seralutinib in PH-ILD by mid-2025 and are considering additional indications.

Gossamer will head worldwide seralutinib development for PAH and PH-ILD indications.

Development expenditures will be shared, other than for the PROSERA study, which remains Gossamer's financial responsibility.

Commercial profits and losses incurred in the US will be divided equally between the companies, with Gossamer handling commercialisation and sales booking for PAH and PH-ILD.

Gossamer Bio and Chiesi will contribute equally to the product’s commercial efforts.

Chiesi will handle the US commercialisation works for any additional indications and exclusively commercialise seralutinib outside the US.

In return, the company will make royalty payments to Gossamer on net product sales.

The agreement stipulates a $160m development reimbursement to Gossamer from Chiesi, along with potential regulatory and sales-based milestone payments of $146m and $180m respectively.

Gossamer co-founder, chairman and CEO Faheem Hasnain stated: “This partnership with Chiesi allows us to meaningfully deepen and rapidly accelerate our investment in seralutinib as a potential treatment for PAH, PH-ILD and other indications of high unmet medical need.

“We are particularly thrilled that this collaboration enables seralutinib to move directly into a Phase III trial in PH-ILD, an indication with a paucity of available treatments, and a disease which we believe seralutinib is specifically designed to address.”

"Gossamer Bio and Chiesi partner for pulmonary hypertension treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Advertisement

Recommended Stories

  • Lina Khan’s noncompete crackdown could leave most doctors and nurses out in the cold

    Provider groups are disappointed that the Federal Trade Commission’s new rule may not protect those who work for nonprofit hospitals and health care facilities, which employ the largest number of medical professionals.

  • Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

    Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

  • Insmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.

    Analysts had said shares could more than double if the trial was a success, or fall by more than half if it failed. The drug brensocatib, treats a condition called bronchiectasis.

  • Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion

    Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion

  • Exact Sciences (EXAS) to Showcase Favorable Research Outcome

    Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

  • Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)

    Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.

  • Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday?

    Insmed Incorporated (NASDAQ:INSM) shares are trading higher after the company released topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis. Non–cystic fibrosis bronchiectasis is a chronic inflammatory condition of the lungs associated with respiratory infections, daily coughing, and sputum. The study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized r

  • Insmed Shares Rocket After Drug Eases Lung Disease Symptoms

    (Bloomberg) -- Insmed Inc. shares more than doubled after the company’s experimental drug reduced episodes of worsening symptoms in a final-stage study of patients with a rare lung condition. Most Read from BloombergWall Street Moves to Fastest Settlement of Trades in a CenturyTreasuries Hit as US Sales Struggle to Lure Buyers: Markets WrapFor Private Credit’s Top Talent, $1 Million a Year Is Not EnoughIsraeli Airstrike and Egyptian Guard’s Death Ratchet Up TensionsCatering to the Ultra-Rich Is

  • The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says

    With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.

  • Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows

    As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.